Search

everythinglearnresearchcommunity

for

Search:↓

A quick and simple method was created to identify minoxidil in hair-growth products using micellar electrokinetic capillary chromatography.

TR3 is mainly found in hair follicle stem cells and may be involved in hair loss.

Targeting METTL1 may help slow papillary thyroid cancer growth and spread.

An automated system can predict death risk in thin melanoma by analyzing immune cells.

Type 3 acromegaly patients have more health issues and higher death risk.

Androgenetic alopecia linked to COVID-19 severity; drugs reducing androgen receptor activation may help.

Procyanidin compounds from apples and barley promote hair growth and prevent hair cell death.

All women with significant unwanted hair growth have hormonal imbalances, often from polycystic ovary syndrome.

Canine hypothyroidism can be linked to diabetes, requiring thorough testing for proper diagnosis.

Most women with excessive hair growth have a hormonal cause.

The Bethesda system is effective for identifying thyroid cancer but has low sensitivity.

Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.

Four new compounds were more effective than finasteride in treating prostate issues and hair loss, with one being 100 times more active and safe for use.

Some people with severe, long-lasting baldness responded well to a specific combination treatment.

A method was created in 2005 to identify minoxidil, a hair growth ingredient, in products using two types of capillary zone electrophoresis, and it found that most products had about 2% minoxidil.

11α-Hydroxyprogesterone is changed into different substances by certain enzymes and may play a role in prostate cancer.

The developed model can predict effective 5-alpha-reductase enzyme inhibitors.

CEC levels may be a useful marker for predicting prostate cancer progression.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

Combining D-004 and finasteride is more effective at reducing prostate enlargement than using either alone.

Gene variation affects prostate issues and hair loss.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

Temozolomide improves survival in grade III glioma patients without harming quality of life.

The new therapy effectively targets brain tumors while minimizing damage to healthy tissue.

Zinc supplements may be needed to treat hair loss in hypothyroidism.

Dupilumab may cause hair loss in some patients with severe atopic dermatitis.

Type 3 5α-reductase is more common and finasteride and dutasteride strongly inhibit it.

Half of the patients treated with a specific drug for skin cancer experienced hair loss not related to the drug's dosage.

Men with hair loss have lower SHBG and higher saliva testosterone levels, suggesting increased androgen activity.

Thyroid hormones affect skin texture, hair and nail growth, and can cause skin diseases related to thyroid problems.